Author:
Santini D.,Vincenzi B.,Addeo R.,Garufi C.,Masi G.,Scartozzi M.,Mancuso A.,Frezza A.M.,Venditti O.,Imperatori M.,Schiavon G.,Bronte G.,Cicero G.,Recine F.,Maiello E.,Cascinu S.,Russo A.,Falcone A.,Tonini G.
Reference34 articles.
1. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model;Goldstein;Clin Cancer Res,1995
2. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study;Bokemeyer;Ann Oncol,2011
3. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer;Tabernero;J Clin Oncol,2007
4. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results;Venook;J Clin Oncol,2006
5. Cetuximab plus FOLFIRI first-line in metastatic colorectal cancer (mCRC): the randomized phase III CRYSTAL trial;Köehne;Ann Oncol,2007
Cited by
177 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献